Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy is often unpredictable. Despite the need for new products in this space, such therapies will struggle to clinically differentiate themselves from current therapies, and a growing generic presence across multiple drug classes will result in increasing market access challenges for branded therapies. In this Access & Reimbursement analysis, how market access barriers shape treatment for NP in the United States is explored, based on collective insight from 100 physicians and 30 MCO PDs/MDs with influence in reimbursement and access of key agents used to treat NP.
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
Markets covered: United States
Key companies: Acorda Therapeutics, Biogen, Depomed, Janssen, NeurogesX, Pfizer, Purdue Pharma, Validus Pharmaceuticals, XenoPort
Key drugs: Lyrica/Lyrica CR, Gralise, Horizant, Equetro, Nucynta ER, OxyContin, Qutenza, vixotrigine (BIIB-074)